Part four of this four part video series from J&J discusses long-acting injectable (LAI) antipsychotics as a treatment option for people with schizophrenia. LAIs provide extended medication coverage, which may help address challenges with daily oral medications. The session highlights how consistent symptom control with LAIs can reduce relapse risk, support independence, and encourage participation in work, relationships, and community life. A patient advocate shares real-world experiences to illustrate potential benefits, and the event is designed for patients, caregivers, and professionals interested in how LAIs may influence outcomes in schizophrenia care.
To learn more, watch the video here.
Contributor: Johnson & Johnson – Dr. Christoph Correll, Dr. Henry Nasrallah, Bethany Yeiser (patient)
